Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Dr Reddy’s Laboratories ( (RDY) ) is now available.
Dr. Reddy’s Laboratories announced that Ms. Archana Bhaskar has resigned from her role as Chief Human Resources Officer (CHRO), effective November 30, 2025. This change in senior managerial personnel is part of the company’s ongoing adjustments and may impact its human resources strategy and operations.
The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories exhibits strong financial health and strategic growth initiatives, particularly in biosimilars and environmental leadership. However, challenges in the U.S. generics market and regulatory issues temper the outlook. The technical indicators suggest a neutral trend, and the valuation appears fair.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a prominent pharmaceutical company based in Hyderabad, India. The company specializes in the production of generic medications, active pharmaceutical ingredients, and proprietary products, with a focus on providing affordable and innovative medicines globally.
Average Trading Volume: 1,443,634
Technical Sentiment Signal: Buy
Current Market Cap: $11.95B
For an in-depth examination of RDY stock, go to TipRanks’ Overview page.